Tegatrabetan

Tegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) [1].

Product Specifications

CAS Number

[1227637-23-1]

Product Name Alternative

Tegavivint; BC2059

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

β-catenin

Type

Reference compound

Related Pathways

Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tegatrabetan.html

Purity

99.84

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(C1=CC2=C(C=C1)/C(C3=CC=C(S(=O)(N4C[C@H](C)C[C@H](C)C4)=O)C=C3/C2=N\O)=N\O)(N5C[C@H](C)C[C@H](C)C5)=O

Molecular Formula

C28H36N4O6S2

Molecular Weight

588.74

Precautions

H302, H315, H319, H335

References & Citations

[1]Fiskus W, et al. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 2015 Jun;29 (6) :1267-78.